AR036027A2 - Un compuesto heterociclico substituido, procedimiento y compuestos intermediarios para su preparacion y composicion farmaceutica que contiene a dicho compuesto - Google Patents
Un compuesto heterociclico substituido, procedimiento y compuestos intermediarios para su preparacion y composicion farmaceutica que contiene a dicho compuestoInfo
- Publication number
- AR036027A2 AR036027A2 ARP020101908A ARP020101908A AR036027A2 AR 036027 A2 AR036027 A2 AR 036027A2 AR P020101908 A ARP020101908 A AR P020101908A AR P020101908 A ARP020101908 A AR P020101908A AR 036027 A2 AR036027 A2 AR 036027A2
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- unsubstituted
- substituted
- group
- hydrogen
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
- C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C215/22—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated
- C07C215/28—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated and containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
- C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C215/22—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated
- C07C215/28—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated and containing six-membered aromatic rings
- C07C215/30—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated and containing six-membered aromatic rings containing hydroxy groups and carbon atoms of six-membered aromatic rings bound to the same carbon atom of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C219/00—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton
- C07C219/02—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C219/20—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated
- C07C219/22—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated and containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
- C07C233/17—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
- C07C233/18—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
- C07C255/32—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring
- C07C255/36—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by hydroxy groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
- C07C255/32—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring
- C07C255/42—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being further bound to other hetero atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
- C07C255/32—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring
- C07C255/42—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being further bound to other hetero atoms
- C07C255/43—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being further bound to other hetero atoms the carbon skeleton being further substituted by singly-bound oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
- C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C271/22—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D263/36—One oxygen atom
- C07D263/38—One oxygen atom attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
- C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
- C07D265/32—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings with oxygen atoms directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D309/10—Oxygen atoms
- C07D309/12—Oxygen atoms only hydrogen atoms and one oxygen atom directly attached to ring carbon atoms, e.g. tetrahydropyranyl ethers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Abstract
Un compuesto heterocíclico sustituido de la fórmula (1) en la cual: -A representa un radical bivalente elegido entre: A1) -O-CO-, A2) -CH2-O-CO-, A3) -O-CH2-CO-, A4) -O-CH2-CH2-, A5) -N(R1)-CO-, A6) -N(R1)-CO-CO-, A7) -N(R1)-CH2-CH2-, A8) -O-CH2-, en los cuales R1 representa un hidrógeno o un alquilo C1-4; -m es 2 ó 3; -Ar1 representa un fenilo no sustituido o sustituido una o varias veces por un sustituyente elegido entre: un átomo de halógeno, un hidroxilo, un alcoxi C1-4, un alquilo C1-4, un trifluorometilo, un metilendioxi, los mencionados sustituyentes siendo idénticos o diferentes; un tienilo no sustituido o sustituido por un átomo de halógeno; un benzotienilo no sustituido o sustituido por un átomo de halógeno; un naftilo no sustituido o sustituido por un átomo de halógeno; un indolilo no sustituido o N-sustituido por un alquilo C1-4 o un bencilo; un imidazolilo no sustituido o sustituido por un átomo de halógeno; un piridilo no sustituido o sustituido por un átomo de halógeno; un bifenilo; -T representa un grupo elegido entre: CH2-Z, -CH(C6H5)2, -C(C6H5)3; T puede además representar el grupo -CO-B-Z cuando A representa un radical bivalente elegido entre: -O-CH2-CH2- ó -N(R1)-CH2-CH2- ó -O-CH2-; -B representa un enlace directo o un metileno; -Z representa: -un fenilo no sustituido o sustituido una o varias veces por un sustituyente elegido entre: un átomo de halógeno; un trifluorometilo; un ciano; un hidroxi; un nitro; un fenilo no sustituido o sustituido una o varias veces por un halógeno, un trifluorometilo, un alquilo C1-4, un hidroxi, un alcoxi C1-4, siendo los mencionados sustituyentes idénticos o diferentes; un amino no sustituido o sustituido una o varias veces por alquilo C1-4; un bencilamino; un carboxi; un alquilo C1-10; un cicloalquilo C3-8 no sustituido o sustituido una o varias veces por un metilo; un alcoxi C1-10; un cicloalquiloxi C3-8 no sustituido o sustituido una o varias veces por un metilo; un mercapto; un alquiltio C1-10; un formiloxi; un alquil C1-6-carboniloxi; un formilamino; un alquil C1-6-carbonilamino; un benzoilamino; un alcoxi C1-4-carbonilo; un cicloalquiloxi C3-7-carbonilo; un cicloalquil C3-7-carbonilo; un carbamoilo no sustituido o sustituido una o dos veces por un alquilo C1-4; un ureido no sustituido o sustituido una o dos veces en posición 3 por un alquilo C1-4 o un cicloalquilo C3-7; un (pirrolidin-1-il)carbonilamino, siendo los mencionados sustituyentes idénticos o diferentes; -un 1- ó 2-naftilo; 1-, 2-, 3-, 4-, 5-, 6-, 7-indenilo, de los cuales una o varias uniones pueden ser hidrogenadas, pudiendo estos grupos ser no sustituidoS o contener eventualmente uno o varios sustituyentes tales como: el grupo alquilo, fenilo, ciano, hidroxialquilo, hidroxi, oxo, alquilcarbonilamino, alcoxicarbonilo, tioalquilo, halógeno, alcoxi y trifluorometilo, en los cuales los alquilos están en C1-4; -un grupo piridilo, tiadiazolilo, indolilo, indazolilo, imidazolilo, bencimidazolilo, benzotriazolilo, benzofuranilo, benzotienilo, benzotiazolilo, bencisotiazolilo, quinolilo, isoquinolilo, benzoxazolilo, bencisoxazolilo, benzoxazinilo, benzodioxinilo, isoxazolilo, benzopiranilo, tiazolilo, tienilo, furilo, piranilo, cromenilo, isobenzofuranilo, pirrolilo, pirazolilo, pirazinilo, pirimidinilo, piridazinilo, indolizinilo, ftalazinilo, quinazolinilo, acridinilo, isotiazolilo, isocromanilo, cromanilo, de los cuales uno o varios dobles enlaces pueden ser hidrogenados, pudiendo dichos grupos ser no sustituido o contener eventualmente uno o varios sustituyentes tales como: el grupo alquilo, fenilo, ciano, hidroxialquilo, hidroxi, alquilcarbonilamino, alcoxicarbonilo, tioalquilo en los cuales los alquilos están en C1-4; -Am representa: i- ya sea un grupo Am1, de fórmula (2) en la cual J1 representa i1- ya sea un grupo Ar2-NR2-CH<; Ar2 representa un piridilo; un fenilo no sustituido o sustituido una o varias veces por un sustituyente elegido entre: un átomo de halógeno, un hidroxi, un alcoxi C1-4, un alquilo C1-4, un trifluorometilo, un nitro, un metilendioxi, los mencionados sustituyentes siendo idénticos o diferentes; un tienilo; un pirimidilo; un imidazolilo no sustituido o sustituido por un alquilo C1-4; R2 representa un hidrógeno; un alquilo C1-7; un bencilo; un formilo; un alquil C1-7-carbonilo; i2- sea un grupo Ar2-(CH2)n-CR3< en el cual: -Ar2 es tal como se ha definido anteriormente; -n es 0 ó 1; -R3 representa un grupo elegido entre: (1) hidrógeno; (2) alquilo C1-7; (3) formilo; (4) alquilcarbonilo C1-7; (5) ciano; (6) -(CH2)q-OH; (7) -(CH2)q-O-alquilo C1-7; (8) -(CH2)q-OCHO; (9) -(CH2)q-OCOR17; (10) -(CH2)q-OCONH-alquilo C1-7; (11) -NR4R5; (12) -(CH2)q-NR6C(=W1)R7; (13) -(CH2)q-NR6COOR8; (14) -(CH2)q-NR6SO2R9; (15) -(CH2)q-NR6C(=W1)NR10R11; (16) -CH2-NR12R13; (17) -CH2-CH2-NR12R13; (18) -COOH; (19) alcoxi C1-7-carbonilo; (20) -C(=W1)NR10R11; (21) -CH2-COOH; (22) alcoxi C1-7-carbonilmetilo; (23) -CH2-C(=W1)NR10R11; (24) -O-CH2CH2-OR18; (25) -NR6COCOR19; (26) -CONR20-NR21R22; (27) un grupo de la fórmula (3); (28) un grupo de la fórmula (4); -o R3 constituye un doble enlace entre el átomo de carbono al cual está unido y el átomo de carbono próximo al ciclo de piperidina; -q es 0, 1 ó 2; -W1 representa un átomo de oxígeno o un átomo de azufre; -R4 y R5 representan cada uno independientemente un hidrógeno o un alquilo C1-7; R5 puede además representar un cicloalquil C3-7-metilo, un bencilo o un fenilo; ó R4 y R5 junto con el átomo de nitrógeno al cual están unidos constituyen un heterociclo elegido entre la azetidina, la pirrolidina, la piperidina, la morfolina, la tiomorfolina, la perhidroazepina o la piperazina no sustituida o sustituida en posición 4 por un alquilo C1-4; -R6 representa un hidrógeno o un alquilo C1-7; -R7 representa un hidrógeno, un alquilo C1-7, un vinilo, un fenilo, un bencilo, un piridilo, un cicloalquilo C3-7 no sustituido o sustituido por uno o varios metilos, un furilo, un tienilo, un pirrolilo, un imidazolilo; ó R6 y R7 juntos representan un grupo -(CH2)p-; -p es 3 ó 4; -R8 representa un alquilo C1-7 o un fenilo; -R9 representa un alquilo C1-7, un amino libre o sustituido por uno o dos alquilos C1-7, un fenilo no sustituido o sustituido una o varias veces por un sustituyente elegido entre: un átomo de halógeno, un alquilo C1-7, un trifluorometilo, un hidroxi, un alcoxi C1-7, un carboxi, un alcoxi C1-7-carbonilo, un alquil C1-7-carboniloxi, un ciano, un nitro, un amino libre o sustituido por uno o dos alquilos C1-7, siendo los mencionados sustituyentes idénticos o diferentes; -R10 y R11 representa cada uno independientemente un hidrógeno o un alquilo C1-7; R11 puede además representar un cicloalquilo C3-7, un cicloalquil C3-7-metilo, un hidroxi, un alcoxi C1-4, un bencilo o un fenilo; ó R10 y R11 juntos con el átomo de nitrógeno al cual están unidos constituyen un heterociclo elegido entre la azetidina, la pirrolidina, la piperidina, la morfolina, la tiomorfolina o la perhidroazepina; -R12 y R13 representan cada uno independientemente un hidrógeno o un alquilo C1-7; R13 puede además representar un cicloalquil C3-7-metilo o un bencilo; -R17 representa un alquilo C1-7; un cicloalquil C3-7-metilo no sustituido o sustituido por uno o varios metilos; un piridilo; un fenilo; un piridilo; -R18 representa un hidrógeno, un alquilo C1-7, un formilo, un alquil C1-7-carbonilo; -R19 representa un alcoxi C1-4; -R20 representa un hidrógeno o un alquilo C1-7; -R21 y R22 representan cada uno independientemente un hidrógeno o un alquilo C1-7; -o bien R21 y R22 juntos con el átomo de nitrógeno al cual están unidos constituyen un heterociclo elegido entre la pirrolidina, la piperidina o la morfolina; -R23 representa un hidrógeno o un alquilo C1-7; -R24 y R25 representan cada uno independientemente un hidrógeno o un alquilo C1-7; R25 puede además representar un formilo o un alquil C1-7-carbonilo; i3 - sea un grupo R14R3C< en el cual -R3 es tal como se ha definido anteriormente; -R14 representa un alquilo C1-7, un cicloalquilo C3-7; R14 puede además representar ya sea un grupo -CONR15R16 cuando R3 representa el hidrógeno, ya sea un grupo -NR15R16 cuando R3 representa el hidrógeno, un ciano, un carboxi, un alcoxi C1-4-carbonilo o un grupo -C(=W1)NR10R11; -R15 y R16 representan cada uno independientemente un alquilo C1-7; o R15 y R16 juntos con el átomo de nitrógeno al cual están unidos constituyen un heterociclo elegido entre la azetidina, la pirrolidina, la piperidina, la morfolina, la tiomorfolina o la perhidroazepina; ii- sea un grupo Am2 de fórmula (5) en la cual J2 representa: ii1 - sea un grupo Ar3R2N-CH< en el cual: -Ar3 representa un fenilo no sustituido o sustituido una o varias veces por un sustituyente elegido entre: un átomo de halógeno, un hidroxi, un alcoxi C1-4, un alquilo C1-4, un trifluorometilo, siendo los mencionados sustituyentes idénticos o diferentes; -R2 es tal como se ha definido anteriormente para J1; ii2 - sea un grupo AR3-(CH2)n-CH- en el cual: -Ar3 es tal como se ha definido anteriormente; -n es 0 ó 1; -Q representa un alquilo C1-6 o un bencilo; estando el mencionado sustituyente en posición axial o en posición ecuatorial; -X- es un anión; iii - sea un grupo Am3 de fórmula (6) en la cual: -Ar2 es tal como se ha definido anteriormente, -n es 0 ó 1; -X- representa un anión; iv - sea un grupo Am4 de fórmula (7) en la cual -Ar2 es tal como se ha definido anteriormente; -n es 0 ó 1; -X- representa un anión; con la condición que cuando A es -O-CH2-CH2-, -N(R1)-CH2-CH2- ó -O-CH2-, m es 2, Ar1 es un fenilo no sustituido o sustituido una o varias veces por un sustituyente elegido entre: un átomo de halógeno, un hidroxi, un alcoxi C1-4, un alquilo C1-4, un trifluorometilo, siendo dichos sustituyentes idénticos o diferentes, T es -CO-Za, siendo Za un fenilo no sustituido o sustituido una o varias veces por un sustituyente elegido entre: un átomo de halógeno, un trifluorometilo, un alquilo C1-10, un alcoxi C1-10, un hidroxi, siendo dichos sustituyentes idénticos o diferent
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR9501016A FR2729952B1 (fr) | 1995-01-30 | 1995-01-30 | Composes heterocycliques substitues, procede pour leur preparation et compositions pharmaceutiques les contenant |
FR9508046A FR2729953B1 (fr) | 1995-01-30 | 1995-07-04 | Composes heterocycliques substitues, procede pour leur preparation et compositions pharmaceutiques les contenant |
FR9513005A FR2729954B1 (fr) | 1995-01-30 | 1995-11-03 | Composes heterocycliques substitues, procede pour leur preparation et compositions pharmaceutiques les contenant |
Publications (1)
Publication Number | Publication Date |
---|---|
AR036027A2 true AR036027A2 (es) | 2004-08-04 |
Family
ID=27253013
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP960101182A AR002955A1 (es) | 1995-01-30 | 1996-01-29 | Un compuesto heterocíclico substituido, procedimiento y compuestos intermediarios para su preparación y composición farmacéutica que contiene a dicho compuesto. |
ARP020101908A AR036027A2 (es) | 1995-01-30 | 2002-05-23 | Un compuesto heterociclico substituido, procedimiento y compuestos intermediarios para su preparacion y composicion farmaceutica que contiene a dicho compuesto |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP960101182A AR002955A1 (es) | 1995-01-30 | 1996-01-29 | Un compuesto heterocíclico substituido, procedimiento y compuestos intermediarios para su preparación y composición farmacéutica que contiene a dicho compuesto. |
Country Status (26)
Country | Link |
---|---|
US (4) | US5641777A (es) |
EP (5) | EP1923391A1 (es) |
JP (4) | JP3234228B2 (es) |
CN (6) | CN1089764C (es) |
AR (2) | AR002955A1 (es) |
AT (2) | ATE222251T1 (es) |
AU (1) | AU707901B2 (es) |
CA (1) | CA2211668C (es) |
CY (2) | CY2369B1 (es) |
CZ (2) | CZ294267B6 (es) |
DE (2) | DE69622992T2 (es) |
DK (2) | DK1156049T3 (es) |
ES (2) | ES2181866T3 (es) |
FI (1) | FI973148A (es) |
FR (1) | FR2729954B1 (es) |
HU (1) | HUP9800295A3 (es) |
IL (3) | IL127114A (es) |
MX (1) | MX9705590A (es) |
MY (1) | MY117527A (es) |
NO (1) | NO308795B1 (es) |
NZ (1) | NZ301285A (es) |
PL (1) | PL192164B1 (es) |
PT (2) | PT1156049E (es) |
RU (1) | RU2157807C2 (es) |
SI (2) | SI0807111T1 (es) |
WO (1) | WO1996023787A1 (es) |
Families Citing this family (54)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2751654B1 (fr) * | 1996-07-26 | 1998-10-23 | Sanofi Sa | Composes heterocycliques substitues, procede pour leur preparation et compositions pharmaceutiques les contenant |
GB9513972D0 (en) * | 1995-07-08 | 1995-09-06 | Merck Sharp & Dohme | Pharmaceutical compositions |
HU224225B1 (hu) * | 1995-12-01 | 2005-06-28 | Sankyo Co. Ltd. | Tachikinin receptor antagonista hatású heterociklusos vegyületek, ezek előállítási eljárása és alkalmazásuk gyógyszerkészítmények előállítására |
GB9601680D0 (en) * | 1996-01-27 | 1996-03-27 | Pfizer Ltd | Therapeutic agents |
FR2759584B1 (fr) * | 1997-02-17 | 1999-06-11 | Sanofi Sa | Composition pharmaceutique pour l'administration orale de composes heterocycliques sous forme ammonium quaternaire |
FR2759585B1 (fr) * | 1997-02-17 | 1999-06-11 | Sanofi Sa | Formulations pharmaceutiques presentees sous forme seche pour l'administration orale d'un compose ammonium quaternaire cyclique |
CA2290392C (en) | 1997-05-30 | 2006-03-28 | Takahide Nishi | Salts of optically active sulfoxide derivative |
ATE297906T1 (de) | 1997-12-04 | 2005-07-15 | Sankyo Co | Alicyclische acylierte heterocyclenderivate |
US6177564B1 (en) * | 1998-09-11 | 2001-01-23 | Merck & Co., Inc. | Process for the synthesis of N-benzyl-3-(4-fluorophenyl)-1-4-oxazin-2-one |
WO2000034274A1 (fr) * | 1998-12-10 | 2000-06-15 | Sankyo Company, Limited | Derives de la cyclohexylpiperidine |
FR2787790A3 (fr) | 1998-12-23 | 2000-06-30 | Sanofi Sa | Procede de preparation du (r)-(+)-3-{1°2-(4-benzoyl-2-(3,4- difluorophenyl)morpholin-2-yl)ethyl!-4-phenylpiperidin-4-yl} -1,1-dimethyluree, de ses sels, solvats et/ou hydrates |
FR2791346B3 (fr) * | 1999-03-25 | 2001-04-27 | Sanofi Sa | Nouveaux derives de morpholine, procede pour leur preparation et compositions pharmaceutiques les contenant |
FR2792199B3 (fr) | 1999-04-13 | 2001-05-18 | Sanofi Sa | Utilisation de l'osanetant pour la preparation de medicaments utiles dans le traitement des troubles de l'humeur |
FR2796069B3 (fr) * | 1999-07-09 | 2001-08-24 | Sanofi Synthelabo | Nouveaux procedes de preparation de derives de 2-(2- arylmorpholin-2-yl)ethanol substitues, enantiomeriquement purs, et composes intermediaires utiles dans ces procedes |
WO2002083134A1 (en) * | 2001-04-12 | 2002-10-24 | Pharmacopeia, Inc. | Aryl and biaryl piperidines used as mch antagonists |
FR2824828B1 (fr) * | 2001-05-21 | 2005-05-20 | Sanofi Synthelabo | Nouveaux derives de piperidinecarboxamide, un procede pour leur preparation et les compositions pharmaceutiques les contenant |
TW200403058A (en) * | 2002-04-19 | 2004-03-01 | Bristol Myers Squibb Co | Heterocyclo inhibitors of potassium channel function |
ATE410426T1 (de) * | 2002-12-13 | 2008-10-15 | Smithkline Beecham Corp | Heterocyclische verbindungen alsccr5-antagonisten |
TW200524868A (en) * | 2003-07-31 | 2005-08-01 | Zeria Pharm Co Ltd | Benzylamine derivatives |
CA2557537A1 (en) * | 2004-02-25 | 2005-09-01 | Sankyo Company Limited | Sulfonyloxy derivatives |
EP1742625A1 (en) * | 2004-04-05 | 2007-01-17 | Sepracor, Inc. | (r,r)-formoterol in combination with other pharmacological agents |
US7955846B2 (en) * | 2004-05-17 | 2011-06-07 | The General Hospital Corporation | Compositions comprising female germline stem cells and methods of use thereof |
GB0412865D0 (en) * | 2004-06-09 | 2004-07-14 | Glaxo Group Ltd | Chemical compounds |
DOP2005000123A (es) | 2004-07-02 | 2011-07-15 | Merck Sharp & Dohme | Inhibidores de cetp |
FR2873373B1 (fr) * | 2004-07-23 | 2006-09-08 | Sanofi Synthelabo | Derives de 4-arylmorpholin-3-one, leur preparation et leur application en therapeutique |
US8835426B2 (en) | 2007-02-26 | 2014-09-16 | Vitae Pharmaceuticals, Inc. | Cyclic urea and carbamate inhibitors of 11β-hydroxysteroid dehydrogenase 1 |
EP2183228B1 (en) | 2007-07-26 | 2014-08-20 | Vitae Pharmaceuticals, Inc. | CYCLIC INHIBITORS OF 11ß -HYDROXYSTERIOD DEHYDROGENASE 1 |
AR069207A1 (es) | 2007-11-07 | 2010-01-06 | Vitae Pharmaceuticals Inc | Ureas ciclicas como inhibidores de la 11 beta - hidroxi-esteroide deshidrogenasa 1 |
CA2708303A1 (en) | 2007-12-11 | 2009-06-18 | Vitae Pharmaceuticals, Inc. | Cyclic urea inhibitors of 11.beta.-hydroxysteroid dehydrogenase 1 |
TW200934490A (en) | 2008-01-07 | 2009-08-16 | Vitae Pharmaceuticals Inc | Lactam inhibitors of 11 &abgr;-hydroxysteroid dehydrogenase 1 |
JP5490020B2 (ja) | 2008-01-24 | 2014-05-14 | ヴァイティー ファーマシューティカルズ,インコーポレイテッド | 11β−ヒドロキシステロイドデヒドロゲナーゼ1の環状カルバゼート及びセミカルバジドインヒビター |
WO2009102428A2 (en) | 2008-02-11 | 2009-08-20 | Vitae Pharmaceuticals, Inc. | 1,3-OXAZEPAN-2-ONE AND 1,3-DIAZEPAN-2-ONE INHIBITORS OF 11β -HYDROXYSTEROID DEHYDROGENASE 1 |
WO2009102460A2 (en) | 2008-02-15 | 2009-08-20 | Vitae Pharmaceuticals, Inc. | Inhibitors of 11beta-hydroxysteroid dehydrogenase 1 |
US20110105504A1 (en) * | 2008-03-18 | 2011-05-05 | Vitae Pharmaceuticals ,Inc. | Inhibitors Of 11beta-Hydroxysteroid Dehydrogenase Type 1 |
CA2723039A1 (en) | 2008-05-01 | 2009-11-05 | Vitae Pharmaceuticals, Inc. | Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1 |
EP2291370B1 (en) | 2008-05-01 | 2013-11-27 | Vitae Pharmaceuticals, Inc. | Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1 |
EP2291373B1 (en) | 2008-05-01 | 2013-09-11 | Vitae Pharmaceuticals, Inc. | Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1 |
JP5301563B2 (ja) | 2008-05-01 | 2013-09-25 | ヴァイティー ファーマシューティカルズ,インコーポレイテッド | 11β−ヒドロキシステロイドデヒドロゲナーゼ1の環状インヒビター |
CN102105454A (zh) | 2008-07-25 | 2011-06-22 | 贝林格尔.英格海姆国际有限公司 | 合成1型11β-羟基类固醇脱氢酶的抑制剂 |
NZ590495A (en) | 2008-07-25 | 2012-10-26 | Vitae Pharmaceuticals Inc | Dihydropyridin-phenyl-3-oxazinan-2-ones as inhibitors of 11beta-hydroxysteroid dehydrogenase 1 |
TW201016691A (en) | 2008-07-25 | 2010-05-01 | Boehringer Ingelheim Int | Inhibitors of 11beta-hydroxysteroid dehydrogenase 1 |
CA2744946A1 (en) | 2009-02-04 | 2010-08-12 | Boehringer Ingelheim International Gmbh | Cyclic inhibitors of 11.beta.-hydroxysteroid dehydrogenase 1 |
TW201039034A (en) * | 2009-04-27 | 2010-11-01 | Chunghwa Picture Tubes Ltd | Pixel structure and the method of forming the same |
KR20120061771A (ko) * | 2009-04-30 | 2012-06-13 | 비타이 파마슈티컬즈, 인코포레이티드 | 11베타-하이드록시스테로이드 탈수소효소 1의 고리형 억제제 |
UA109255C2 (ru) | 2009-04-30 | 2015-08-10 | Берінгер Інгельхайм Інтернешнл Гмбх | Циклические ингибиторы 11бета-гидроксистероиддегидрогеназы 1 |
WO2011011123A1 (en) | 2009-06-11 | 2011-01-27 | Vitae Pharmaceuticals, Inc. | Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1 based on the 1,3 -oxazinan- 2 -one structure |
EP2448928B1 (en) | 2009-07-01 | 2014-08-13 | Vitae Pharmaceuticals, Inc. | Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1 |
US8552212B2 (en) | 2009-11-05 | 2013-10-08 | Boehringer Ingelheim International Gmbh | Chiral phosphorus ligands |
MY159958A (en) * | 2009-12-18 | 2017-02-15 | Idenix Pharmaceuticals Inc | 5,5-fused arylene or heteroarylene hepatitis c virus inhibitors |
KR101756495B1 (ko) | 2010-03-11 | 2017-07-10 | 다이닛본 스미토모 세이야꾸 가부시끼가이샤 | N-아실 시클릭 아민 유도체 또는 이의 의약상 허용되는 염 |
JP2013531636A (ja) | 2010-05-26 | 2013-08-08 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 2−オキソ−1,2−ジヒドロピリジン−4−イルボロン酸誘導体 |
US8933072B2 (en) | 2010-06-16 | 2015-01-13 | Vitae Pharmaceuticals, Inc. | Substituted 5-,6- and 7-membered heterocycles, medicaments containing such compounds, and their use |
JP5813106B2 (ja) | 2010-06-25 | 2015-11-17 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 代謝障害の処置のための11−β−HSD1のインヒビターとしてのアザスピロヘキサノン |
CA2813671A1 (en) | 2010-11-02 | 2012-05-10 | Boehringer Ingelheim International Gmbh | Pharmaceutical combinations for the treatment of metabolic disorders |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2398575A (en) * | 1946-04-16 | Theib manufacture | ||
US2382285A (en) * | 1941-11-19 | 1945-08-14 | Roche Products Ltd | Manufacture of arylacetonitrile derivatives |
US2513346A (en) * | 1948-12-21 | 1950-07-04 | Parke Davis & Co | Process for obtaining organic amino diols |
US2689852A (en) * | 1951-11-03 | 1954-09-21 | Hoffmann La Roche | Pyridine derivatives |
US3112311A (en) * | 1957-04-05 | 1963-11-26 | Geigy Chem Corp | 2-phenyl-5, 6-dimethyl-morpholines and 2-phenyl-5, 6-tetramethylene-morpholines |
GB1016828A (en) * | 1961-11-13 | 1966-01-12 | Mcneilab Inc | Substituted morpholines and process for preparing same |
GB8807921D0 (en) | 1988-04-05 | 1988-05-05 | Fujisawa Pharmaceutical Co | Ws-9326 & its derivatives |
US5147006A (en) | 1988-08-12 | 1992-09-15 | Volkswagen Ag | Friction clutch |
WO1990005525A1 (en) | 1988-11-23 | 1990-05-31 | Pfizer Inc. | Quinuclidine derivatives as substance p antagonists |
IE903957A1 (en) * | 1989-11-06 | 1991-05-08 | Sanofi Sa | Aromatic amine compounds, their method of preparation and¹pharmaceutical compositions in which they are present |
FR2654726B1 (fr) | 1989-11-23 | 1992-02-14 | Rhone Poulenc Sante | Nouveaux derives de l'isoindolone et leur preparation. |
WO1991009844A1 (en) | 1990-01-04 | 1991-07-11 | Pfizer Inc. | Substance p antagonists |
US5332817A (en) * | 1990-01-04 | 1994-07-26 | Pfizer Inc. | 3-aminopiperidine derivatives and related nitrogen containing heterocycles |
ATE113947T1 (de) | 1990-06-01 | 1994-11-15 | Pfizer | 3-amino-2-arylchinuclidine, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zubereitungen. |
IL99320A (en) * | 1990-09-05 | 1995-07-31 | Sanofi Sa | Arylalkylamines, their preparation and pharmaceutical preparations containing them |
FR2676054B1 (fr) * | 1991-05-03 | 1993-09-03 | Sanofi Elf | Nouveaux composes n-alkylenepiperidino et leurs enantiomeres, procede pour leur preparation et compositions pharmaceutiques les contenant. |
FR2676055B1 (fr) * | 1991-05-03 | 1993-09-03 | Sanofi Elf | Composes polycycliques amines et leurs enantiomeres, procede pour leur preparation et compositions pharmaceutiques les contenant. |
FR2688219B1 (fr) * | 1992-03-03 | 1994-07-08 | Sanofi Elf | Sels d'ammonium quaternaires de composes aromatiques amines, leur preparation et compositions pharmaceutiques les contenant. |
IL106142A (en) * | 1992-06-29 | 1997-03-18 | Merck & Co Inc | Morpholine and thiomorpholine tachykinin receptor antagonists, their preparation and pharmaceutical compositions containing them |
FR2696178B1 (fr) * | 1992-09-30 | 1994-12-30 | Sanofi Elf | Amides basiques quaternaires, procédé pour leur préparation et compositions pharmaceutiques en contenant. |
CA2160462C (en) * | 1993-05-06 | 1998-12-15 | Timothy P. Burkholder | Substituted pyrrolidin-3-yl-alkyl-piperidines useful as tachykinin antagonists |
-
1995
- 1995-11-03 FR FR9513005A patent/FR2729954B1/fr not_active Expired - Fee Related
-
1996
- 1996-01-26 MY MYPI96000294A patent/MY117527A/en unknown
- 1996-01-29 AR ARP960101182A patent/AR002955A1/es active IP Right Grant
- 1996-01-30 WO PCT/FR1996/000152 patent/WO1996023787A1/fr active IP Right Grant
- 1996-01-30 IL IL12711496A patent/IL127114A/en not_active IP Right Cessation
- 1996-01-30 MX MX9705590A patent/MX9705590A/es not_active IP Right Cessation
- 1996-01-30 PL PL321640A patent/PL192164B1/pl not_active IP Right Cessation
- 1996-01-30 PT PT01119949T patent/PT1156049E/pt unknown
- 1996-01-30 SI SI9630532T patent/SI0807111T1/xx unknown
- 1996-01-30 AT AT96902305T patent/ATE222251T1/de active
- 1996-01-30 AT AT01119949T patent/ATE296823T1/de active
- 1996-01-30 CZ CZ20022243A patent/CZ294267B6/cs not_active IP Right Cessation
- 1996-01-30 PT PT96902305T patent/PT807111E/pt unknown
- 1996-01-30 ES ES96902305T patent/ES2181866T3/es not_active Expired - Lifetime
- 1996-01-30 CZ CZ19972436A patent/CZ293134B6/cs not_active IP Right Cessation
- 1996-01-30 AU AU46669/96A patent/AU707901B2/en not_active Ceased
- 1996-01-30 EP EP07150446A patent/EP1923391A1/fr not_active Withdrawn
- 1996-01-30 IL IL11605796A patent/IL116957A0/xx unknown
- 1996-01-30 DK DK01119949T patent/DK1156049T3/da active
- 1996-01-30 CN CN96191686A patent/CN1089764C/zh not_active Expired - Fee Related
- 1996-01-30 EP EP01119949A patent/EP1156049B1/fr not_active Expired - Lifetime
- 1996-01-30 DE DE69622992T patent/DE69622992T2/de not_active Expired - Lifetime
- 1996-01-30 ES ES01119949T patent/ES2243373T3/es not_active Expired - Lifetime
- 1996-01-30 RU RU97114938/04A patent/RU2157807C2/ru not_active IP Right Cessation
- 1996-01-30 CN CNB200310119883XA patent/CN1293063C/zh not_active Expired - Fee Related
- 1996-01-30 DE DE69634806T patent/DE69634806T2/de not_active Expired - Lifetime
- 1996-01-30 DK DK96902305T patent/DK0807111T3/da active
- 1996-01-30 HU HU9800295A patent/HUP9800295A3/hu unknown
- 1996-01-30 SI SI9630713T patent/SI1156049T1/xx unknown
- 1996-01-30 CA CA002211668A patent/CA2211668C/en not_active Expired - Fee Related
- 1996-01-30 US US08/593,938 patent/US5641777A/en not_active Expired - Lifetime
- 1996-01-30 EP EP06005775A patent/EP1688416A1/fr not_active Withdrawn
- 1996-01-30 EP EP96902305A patent/EP0807111B1/fr not_active Expired - Lifetime
- 1996-01-30 JP JP52330896A patent/JP3234228B2/ja not_active Expired - Lifetime
- 1996-01-30 IL IL11695796A patent/IL116957A/xx not_active IP Right Cessation
- 1996-01-30 CN CNB2004100929315A patent/CN1295221C/zh not_active Expired - Fee Related
- 1996-01-30 NZ NZ301285A patent/NZ301285A/xx not_active IP Right Cessation
- 1996-01-30 EP EP03012771A patent/EP1340754A1/fr not_active Withdrawn
-
1997
- 1997-03-18 US US08/820,716 patent/US5869663A/en not_active Expired - Lifetime
- 1997-07-29 FI FI973148A patent/FI973148A/fi not_active Application Discontinuation
- 1997-07-29 NO NO973479A patent/NO308795B1/no not_active IP Right Cessation
-
1998
- 1998-10-20 US US09/175,331 patent/US6242637B1/en not_active Expired - Fee Related
- 1998-10-20 US US09/175,332 patent/US5977359A/en not_active Expired - Lifetime
-
2000
- 2000-11-09 JP JP2000342606A patent/JP2001131171A/ja active Pending
- 2000-11-09 JP JP2000342571A patent/JP3357660B2/ja not_active Expired - Lifetime
-
2001
- 2001-04-11 CN CNB011163402A patent/CN1136189C/zh not_active Expired - Fee Related
- 2001-04-11 CN CNB011163410A patent/CN1179954C/zh not_active Expired - Fee Related
- 2001-11-05 JP JP2001339406A patent/JP3943369B2/ja not_active Expired - Fee Related
- 2001-12-07 CN CNB011431032A patent/CN1202093C/zh not_active Expired - Fee Related
-
2002
- 2002-05-23 AR ARP020101908A patent/AR036027A2/es active IP Right Grant
-
2003
- 2003-08-04 CY CY0300053A patent/CY2369B1/xx unknown
-
2005
- 2005-08-02 CY CY0500044A patent/CY2537B1/xx unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR036027A2 (es) | Un compuesto heterociclico substituido, procedimiento y compuestos intermediarios para su preparacion y composicion farmaceutica que contiene a dicho compuesto | |
AR015774A1 (es) | Derivados de epotilona 12,13-modificados y sus sales | |
AR036042A1 (es) | Derivados aralquilsufonil-3-(pirrol-2-ilmetiliden)-2-indolinona, sus composiciones farmaceuticas y metodo para la modulacion de la actividad catalitica de una proteina quinasa | |
CA2124206A1 (en) | Indole derivatives | |
ATE206611T1 (de) | Verwendung von mangiferin oder seinen derivaten zur kosmetischen anwendung | |
FR2674851B1 (fr) | Derives s-triaziniques portant des substituants benzylidene camphre, compositions cosmetiques filtrantes et leur utilisation pour proteger la peau et les cheveux du rayonnement ultraviolet. | |
AR030432A1 (es) | Uso de derivados de quinazolina en la preparacion de un medicamento para ser usado en la inhibicion de la quinasa aurora2, compuestos relacionados, y composicion farmaceutica. | |
AR036906A1 (es) | Compuestos de imidazopiridin como moduladores del receptor 5-ht4 | |
AR073740A1 (es) | Compuestos para el tratamiento de la hepatitis c | |
ATE279406T1 (de) | Piperidinderivate mit tachykinin-antagonistischer wirkung | |
ES2188194T3 (es) | 1,8-naftiridin-4(1h)-onas sustituidas como inhibidores de la fosfodiesterasa 4. | |
AR050619A1 (es) | Derivados de adamantilo | |
TR199901259T2 (xx) | Nos inhibit�rleri olarak fayda ta��yan 6-fenilpiridil-2-amin t�revleri | |
BG62615B1 (en) | (imidazol-5-yl)methyl-2-quinoline derivatives inhibiting pharnesyl protein transferase | |
AR035069A1 (es) | Compuestos inhibidores de espiropirimidin-2,4,6-triona metaloproteinasas, composicion farmaceutica, procedimiento de tratamiento | |
SE9702799D0 (sv) | New compounds | |
FI962749A0 (fi) | Uusia heterosyklisiä yhdisteitä | |
NZ334377A (en) | use of ketone substituted indanone derivatives for treating cell proliferation disorders and compositions thereof | |
NO20014529D0 (no) | Tetrahydropyranderivater og deres anvendelse som terapautiske midler | |
PE20020759A1 (es) | Derivados de bencilamina con base prolina como inhibidores de trombina | |
TR200000414T2 (tr) | 2-(4-Aril ya da heteroaril-piperazin-1-ilmetil)-1H-indol türevleri. | |
KR930007969A (ko) | 17β- 치환된 아자 - 안드로스탄 유도체 | |
AR026225A1 (es) | Compuestos relacionados con el sistema del periodo circadiano | |
NO20000063L (no) | Nye IL-5 inhiberende 6-azauracilderivater | |
AR011964A1 (es) | Un compuesto derivado de (1h-indol-2-il)-5-[(2h-pirrol-2-ilideno)metil]-1h- pirrol, su utilizacion, un procedimiento para producirlo, productos ycomposiciones farmaceuticas que comprenden a dicho compuesto, un compuesto util como intermediario para preparar a dicho compuesto y una preparacion de |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant, registration |